US Pharma MarketingGenprex’s Reqorsa combo secures Canadian patent for lung cancer
Genprex has received a Notice of Allowance from the CIPO for a patent related to the use of its Reqorsa gene therapy in combination with either PD-1 or PD-L1 antibodies to treat NSCLC and SCLC. Reqorsa is currently in development alongside approved cancer drugs. Genprex is conducting the Acclaim-3 Phase I/II clinical trial, assessing the combination of Reqorsa and Genentech’s Tecentriq. Credit: AnnaStills / Shutterstock.com. Genprex has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for a patent related to the use of its Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with either programmed cell death…
Genprex has received a Notice of Allowance from the CIPO for a patent related to the use of its Reqorsa gene therapy in combination with either PD-1 or PD-L1 antibodies to treat NSCLC and SCLC.
Source: Pharmaceutical Technology